Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Lufax Holding Ltd (LU) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Lufax Holding Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while Lufax Holding Ltd trades at $1.31 (market cap $2.41B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 16.6× Lufax Holding Ltd's market cap. Which is the better fit depends on your goals.
| ALNY | LU | |
|---|---|---|
Market Cap | $39.89B | $2.41B |
Sector | Health | Technology |
52-Week High | $491.22 | $4.40 |
52-Week Low | $278.09 | $1.23 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
LU trades at $1.34, down 1.47% today, with a neutral technical signal and bearish moving averages. The company reported 2025 revenue of $23.1B but a net loss of $2.1B, with negative profit margins. Analyst consensus is 62% buy, but recent news highlights multiple class-action lawsuits filed against the company, creating significant legal overhangs. Cash flow trends show negative net cash flow of $709M in 2025, driven by heavy investing outflows.
The outlook is mixed: low valuation ratios (P/S 0.34, P/B 0.1) suggest potential upside if profitability improves, but persistent losses, legal risks, and negative cash flow pose substantial downside risks. Investors should weigh cheap valuation against execution challenges and litigation uncertainties in the near term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
